ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hansen, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hansen, N.
Eur Respir J 1989; 2: 716-720
Copyright © ERS Journals Ltd 1989


Clinical Trial

Terbutaline as powder inhalation from Bricanyl Turbuhaler compared to terbutaline as nebulizer solution in severe chronic airways obstruction

NC Hansen

Twenty two adults with severe chronic airways obstruction--FEV1 from 14 to 57% of predicted--participated on two consecutive days in an open cross over comparison of inhalation of 2 mg terbutaline powder by Bricanyl Turbuhaler and 5 mg terbutaline by a conventional jet nebulizer (Pari Inhalierboy). All participants were domiciliary users of nebulized terbutaline previous to inclusion in this study. The mean (SD) maximal increase in FEV1 within the 60 minutes following inhalation by Turbuhaler and by Pari Inhalierboy was 27% (15%) and 28% (15%). The mean (SD) maximal increase in FVC was 30% (20%) and 29% (16%). The differences were not statistically significant. All participants were able to produce inspiratory flows high enough to use the Turbuhaler. The study suggests that it will be possible to replace the use of nebulizers with powder inhalations, as far as the bronchodilating effects are concerned.


This article has been cited by other articles:


Home page
Chronic Respiratory DiseaseHome page
C. Brophy, J. Kastelik, E. Gardiner, and M. Greenstone
Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD
Chronic Respiratory Disease, February 1, 2008; 5(1): 13 - 18.
[Abstract] [PDF]


Home page
ChestHome page
M. B. Dolovich, R. C. Ahrens, D. R. Hess, P. Anderson, R. Dhand, J. L. Rau, G. C. Smaldone, and G. Guyatt
Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology
Chest, January 1, 2005; 127(1): 335 - 371.
[Abstract] [Full Text] [PDF]


Home page
Qual Saf Health CareHome page
J Wright, D Brocklebank, and F Ram
Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD)
Qual. Saf. Health Care, January 12, 2002; 11(4): 376 - 382.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. Epstein, A. Maidenberg, D. Hallett, K. Khan, and K. R. Chapman
Patient Handling of a Dry-Powder Inhaler in Clinical Practice
Chest, November 1, 2001; 120(5): 1480 - 1484.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the European Respiratory Society.